Tech Company Financing Transactions

HemaQuest Pharmaceuticals Funding Round

On 3/12/2012, HemaQuest Pharmaceuticals received $13 million in Series B funding from Aberdare Ventures, De Novo Ventures and Forward Ventures.

Transaction Overview

Company Name
HemaQuest Pharmaceuticals
Announced On
3/12/2012
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Series B
Investors

Aberdare Ventures (Naheed Misfeldt)

De Novo Ventures (Fred Dotzler)

Forward Ventures (Ivor Royston)

Latterell Venture Partners (James Woody)

Lilly Ventures (Armen Shanafelt)

Proceeds Purpose
Proceeds from the financing will be used to fund a randomized, double-blind, placebo-controlled Phase 2b clinical study evaluating lead product candidate HQK-1001 in patients with sickle cell disease. The Company believes this financing, combined with existing cash balances, will be sufficient to allow completion of the Phase 2b trial and to fund operations through early 2014.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
11995 El Camino Real 302
San Diego, CA 92130
USA
Phone
(858) 356-5590
Website
www.hemaquest.com
Email Address
[email protected]
Overview
HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders.
Profile
HemaQuest Pharmaceuticals LinkedIn Company Profile
Social Media
HemaQuest Pharmaceuticals Company Twitter Account
Company News
HemaQuest Pharmaceuticals News
Facebook
HemaQuest Pharmaceuticals on Facebook
YouTube
HemaQuest Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Longenecker
  John Longenecker LinkedIn Profile  John Longenecker Twitter Account  John Longenecker News  John Longenecker on Facebook
Chief Financial Officer
Tamara Seymour
  Tamara Seymour LinkedIn Profile  Tamara Seymour Twitter Account  Tamara Seymour News  Tamara Seymour on Facebook
Chief Medical Officer
Richard Ghalie
  Richard Ghalie LinkedIn Profile  Richard Ghalie Twitter Account  Richard Ghalie News  Richard Ghalie on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/12/2012: Allylix venture capital transaction
Next: 3/12/2012: Bellicum Pharmaceuticals venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.